Journal of Diabetes and Its Complications
Volume 25, Issue 2 , Pages 122-128 , March 2011

High-dose insulin in experimental myocardial infarction in rabbits: protection against effects of hyperglycaemia

  • Vincent W. Wong

      Affiliations

    • Department of Cardiology, Royal North Shore Hospital, Sydney, NSW 2065, Australia
    • Diabetes Centre, Liverpool Hospital, Sydney, Australia
    • ,
  • Mahidi Mardini

      Affiliations

    • Department of Cardiology, Royal North Shore Hospital, Sydney, NSW 2065, Australia
    • The University of Sydney, Sydney, Australia
    • Department of Cardiology, Westmead Hospital
    • ,
  • N. Wah Cheung

      Affiliations

    • The University of Sydney, Sydney, Australia
    • Department of Diabetes and Endocrinology, Westmead Hospital
    • ,
  • Anastasia S. Mihailidou

      Affiliations

    • Department of Cardiology, Royal North Shore Hospital, Sydney, NSW 2065, Australia
    • The University of Sydney, Sydney, Australia
    • Corresponding Author InformationCorresponding author. Department of Cardiology, Royal North Shore Hospital, Pacific Highway, St. Leonards, Sydney, NSW 2065, Australia. Tel.: +61 2 992 64956; fax: +61 2 922 65144.

Received 7 September 2009 ,Revised 20 December 2009 ,Accepted 27 January 2010.

References 

  1. Ambrosio G, Flaherty JT. Effects of the superoxide radical scavenger superoxide dismutase, and of the hydroxyl radical scavenger mannitol, on reperfusion injury in isolated rabbit hearts. Cardiovascular Drugs and Therapy. 1992;6:623–632
  2. Apstein CS. Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury. American Heart Journal. 2000;139:S107–S114
  3. Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, et al. Fasting glucose in acute myocardial infarction: Incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care. 2007;30:960–966
  4. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phospatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Research in Cardiology. 1999;94:188–198
  5. Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. American Journal of Cardiology. 1989;64:885–888
  6. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. Journal of the American College of Cardiology. 2002;39:30–36
  7. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938–1948
  8. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. Lancet. 2000;355:773–778
  9. Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, et al. ATP synthesis during low-flow ischemia: Influence of increased glycolytic substrate. Circulation. 2000;101:2090–2096
  10. Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Experimental Cell Research. 1996;226:316–327
  11. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: A randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765–770
  12. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: Relevance to cardiovascular disease. Journal of the American College of Cardiology. 2007;99:15B–26B
  13. De Sutter J, Tavernier R, Van de Wiele C, Kazmierckzak J, De Buyzere M, Jordaens L, et al. Infarct size and recurrence of ventricular arrhythmias after defibrillator implantation. European Journal of Nuclear Medicine. 2000;27:807–815
  14. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation. 1998;98:2227–2234
  15. Esposito K, Marfella R, Giugliano D. Hyperglycemia and heart dysfunction: An oxidant mechanism contributing to heart failure in diabetes. Journal of Endocrinological Investigation. 2002;25:485–488
  16. Falck G, Schjott J, Jynge P. Hyperosmotic pretreatment reduces infarct size in the rat heart. Physiological Research. 1999;48:331–340
  17. Gan RM, Wong VW, Cheung NW, Mclean M. Effect of insulin infusion on electrographic findings following acute myocardial infarction: Importance of glycaemic control. Diabetic Medicine. 2009;26:174–176
  18. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation. 2002;105:1497–1502
  19. Garcia-Dorado D, Theroux P, Munoz R, Alonso J, Elizaga J, Fernandez-Aviles F, et al. Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size. American Journal of Physiology. Heart and Circulatory Physiology. 1992;262:H17–H22
  20. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. Journal of Clinical Investigation. 1994;94:1621–1628
  21. Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P, et al. Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabetic Medicine. 2004;21:305–310
  22. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovascular Drugs and Therapy. 2000;14:615–623
  23. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. Journal of Molecular and Cellular Cardiology. 2000;32:757–764
  24. Justicz AG, Farnsworth WV, Soberman MS, Tuvlin MB, Bonner GD, Bonner GD, et al. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. American Heart Journal. 1991;122:671–680
  25. Kosiborod M, Inzucchi SE, Krumholz HM. Glucometrics in patients hospitalized with acute myocardial infarction: Defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018–1271
  26. LaDisa JF, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Cardioprotection by glucose-insulin-potassium: Dependence on KATP channel opening and blood glucose concentration before ischemia. American Journal of Physiology. Heart and Circulatory Physiology. 2004;287:H601–H607
  27. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. Journal of the American College of Cardiology. 1995;26:57–65
  28. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. European Heart Journal. 2005;26:650–661
  29. Marfella R, D'Amico M, Di Filippo C, Piegari E, Nappo F, Esposito K, et al. Myocardial infarction in diabetic rats: Role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia. 2002;45:1172–1181
  30. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. Journal of the American Medical Association. 2005;293:437–446
  31. Miller TD, Hodge DO, Sutton JM, Grines CL, O'Keefe JH, DeWood MA, et al. Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. Journal of the American College of Cardiology. 1998;81:1491–1493
  32. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790
  33. Oliver MF. Antilipolytic drugs for the prevention of primary ventricular fibrillation. Diabetes, Obesity & Metabolism. 2001;3:61–65
  34. Olivetti G, Quaini F, Sala R, Lagrasta C, Corradi D, Bonacina E, et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. Journal of Molecular and Cellular Cardiology. 1996;28:2005–2016
  35. Pisarenko OI, Serebryakova LI, Studneva IM, Tskitishvili OV. Metabolic correction reduces the area of acute ischemic myocardial infarction in rats. Bulletin of Experimental Biology and Medicine. 2006;141:296–298
  36. Rasoul S, Ottervanger JP, Timmer JR, Svilaas T, Henriques JP, Dambrink JH, et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. International Journal of Cardiology. 2007;122(1):52–55
  37. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985;8:230–234
  38. Shizukuda Y, Reyland ME, Buttrick PM. Protein kinase C-delta modulates apoptosis induced by hyperglycemia in adult ventricular myocytes. American Journal of Physiology. Heart and Circulatory Physiology. 2002;282:H1625–H1634
  39. Su H, Sun X, Ma H, Zhang HF, Yu QJ, Huang C, et al. Acute hyperglycemia exacerbates myocardial ischemia/reperfusion injury and blunts cardioprotective effect of GIK. American Journal of Physiology. Endocrinology and Metabolism. 2007;293:E629–E635
  40. Sundell J, Knuuti J. Insulin and myocardial blood flow. Cardiovasc Res. 2003;57:312–319
  41. Tansey MJ, Opie LH. Plasma glucose on admission to hospital as a metabolic index of the severity of acute myocardial infarction. Canadian Journal of Cardiology. 1985;2:326–331
  42. Tune JD, Mallet RT, Downey HF. Insulin improves contractile function during moderate ischemia in canine left ventricle. American Journal of Physiology. Heart and Circulatory Physiology. 1998;74:H1574–H1581
  43. van der Horst IC, Zijlstra F, van't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: The glucose-insulin-potassium study: A randomized trial. Journal of the American College of Cardiology. 2003;42:784–791
  44. Wong VW, Ross DL, Park K, Boyages SC, Cheung NW. Hyperglycemia Still an important Predictor of Adverse Outcomes following AMI in the reperfusion era. Diabetes Research and Clinical Practice. 2004;64:85–91
  45. Zeller M, Verges B, L'Huillier I, Brun JM, Cottin Y. Glycemia in acute coronary syndromes. Diabetes & Metabolism. 2006;32(2):S42–S47

PII: S1056-8727(10)00002-4

doi: 10.1016/j.jdiacomp.2010.01.001

Journal of Diabetes and Its Complications
Volume 25, Issue 2 , Pages 122-128 , March 2011

Article Tools

* Image Usage & Resolution